Vascular specialists at the 2nd Military Medical University-Shanghai Hospital, the 2nd Affiliated Hospital of Harbin Medical University, Jiangsu Province People’s Hospital and Peking University People’s Hospital, China, recently performed the initial implants of a branched stent graft system (Microport).
The use of the system marks, according to a press release, the world’s first-in-human multicentre clinical trial of the Castor branched stent graft, which is expected to be carried out at 11 centres in China.
Jing Zaiping, the study’s primary investigator, according to the release, has successfully used the Castor branched aortic stent graft system in ten cases as of the end of June.
Castor is designed for the entirely endovascular treatment of thoracic dissection encroaching on the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. According to the company, Castor has an easy-for-use unibody design, including a main body and a left subclavian branch graft. The invention of Castor branched stent-graft system makes it possible to treat a large number of patients with dissection across the aortic arch safely and less invasively.